2016
DOI: 10.18632/oncotarget.11644
|View full text |Cite
|
Sign up to set email alerts
|

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses

Abstract: Trans-arterial radioembolization (TARE) is a recognized, although not explicitly recommended, experimental therapy for unresectable hepatocellular carcinoma (HCC).A systematic literature review was performed to identify published studies on the use of TARE in intermediate and advanced stages HCC exploring the efficacy and safety of this innovative treatment.Twenty-one studies reporting data on overall survival (OS) and time to progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 63%… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
51
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
8
2

Relationship

3
7

Authors

Journals

citations
Cited by 63 publications
(53 citation statements)
references
References 49 publications
(53 reference statements)
2
51
0
Order By: Relevance
“…Of note, all of the included studies recruited patients who progressed on sorafenib, therefore the eventual role of regorafenib in the first-line setting is unknown. Further studies are needed in order to evaluate the competitive role of regorafenib with other systemic agents [24], in particular sorafenib, and with transarterial radioembolization in intermediate/advanced HCC patients with portal vein invasion [25][26][27].…”
Section: Discussionmentioning
confidence: 99%
“…Of note, all of the included studies recruited patients who progressed on sorafenib, therefore the eventual role of regorafenib in the first-line setting is unknown. Further studies are needed in order to evaluate the competitive role of regorafenib with other systemic agents [24], in particular sorafenib, and with transarterial radioembolization in intermediate/advanced HCC patients with portal vein invasion [25][26][27].…”
Section: Discussionmentioning
confidence: 99%
“…Hepatocellular carcinoma (HCC) is the fifth most commonly occurring type of cancer and the leading cause of mortality in cirrhotic patients [1]. Despite the recent improvement in diagnosis and screening programs in cirrhotics, a great number of patients are still diagnosed in the advanced stage, thus being unsuitable to curative treatments, such as surgery, orthotopic liver transplantation, or radiofrequency ablation [2][3][4]. Therefore, the identification of prognostic factors for HCC occurrence is of paramount importance in order to decrease the burden of this disease, in particular in high-risk populations, such as cirrhotic or chronic hepatitis B virus (HBV) patients.…”
Section: Introductionmentioning
confidence: 99%
“…The evidence that supports the use of TARE in HCC treatment is mainly based on retrospective or prospective observational studies [12][13][14][15][16], and no cost-effectiveness analyses have been performed comparing the use of TARE with that of sorafenib for the treatment of patients with HCC. Two randomized controlled trials (RCTs) comparing TARE with sorafenib are ongoing at present (YES-P: NCT01887717; SARAH: NCT01482442).…”
Section: Introductionmentioning
confidence: 99%